Legal status
Legal status
  • In general: uncontrolled
  • 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4-benzoxazepin-5(4H)-one
CAS Number
PubChem CID
Chemical and physical data
Molar mass409.91 g·mol−1
3D model (JSmol)
  • InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2 ☒N
 ☒NcheckY (what is this?)  (verify)

Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

See also


  1. ^ Kamei K, Maeda N, Nomura K, Shibata M, Katsuragi-Ogino R, Koyama M, et al. (March 2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry. 14 (6): 1978–92. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.
  2. ^ Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–30. doi:10.1159/000091712. PMID 16651823. S2CID 39193793.
  3. ^ Mondick JT, Oo C, Patel D, Fujitani T, Shimizu K, Barrett JS (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American Journal of Therapeutics. 16 (2): 106–15. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037. S2CID 21284395.